Comprehensive identification of SUMO2/3 targets and their dynamics during mitosis

PLoS One. 2014 Jun 27;9(6):e100692. doi: 10.1371/journal.pone.0100692. eCollection 2014.

Abstract

During mitosis large alterations in cellular structures occur rapidly, which to a large extent is regulated by post-translational modification of proteins. Modification of proteins with the small ubiquitin-related protein SUMO2/3 regulates mitotic progression, but few mitotic targets have been identified so far. To deepen our understanding of SUMO2/3 during this window of the cell cycle, we undertook a comprehensive proteomic characterization of SUMO2/3 modified proteins in mitosis and upon mitotic exit. We developed an efficient tandem affinity purification strategy of SUMO2/3 modified proteins from mitotic cells. Combining this purification strategy with cell synchronization procedures and quantitative mass spectrometry allowed for the mapping of numerous novel targets and their dynamics as cells progressed out of mitosis. This identified RhoGDIα as a major SUMO2/3 modified protein, specifically during mitosis, mediated by the SUMO ligases PIAS2 and PIAS3. Our data provide a rich resource for further exploring the role of SUMO2/3 modifications in mitosis and cell cycle regulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Amino Acid Substitution
  • Benzamides / pharmacology
  • Chromatography, High Pressure Liquid
  • HeLa Cells
  • Humans
  • Mitosis*
  • Molecular Sequence Data
  • Paclitaxel / pharmacology
  • Prometaphase
  • Proteomics
  • Quinazolines / pharmacology
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Small Ubiquitin-Related Modifier Proteins / chemistry
  • Small Ubiquitin-Related Modifier Proteins / genetics
  • Small Ubiquitin-Related Modifier Proteins / metabolism*
  • Sumoylation / drug effects
  • Tandem Mass Spectrometry
  • Ubiquitins / chemistry
  • Ubiquitins / genetics
  • Ubiquitins / metabolism*
  • rho Guanine Nucleotide Dissociation Inhibitor alpha / antagonists & inhibitors
  • rho Guanine Nucleotide Dissociation Inhibitor alpha / genetics
  • rho Guanine Nucleotide Dissociation Inhibitor alpha / metabolism
  • rho Guanine Nucleotide Dissociation Inhibitor beta / antagonists & inhibitors
  • rho Guanine Nucleotide Dissociation Inhibitor beta / genetics
  • rho Guanine Nucleotide Dissociation Inhibitor beta / metabolism

Substances

  • 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline
  • Benzamides
  • Quinazolines
  • RNA, Small Interfering
  • SUMO2 protein, human
  • SUMO3 protein, human
  • Small Ubiquitin-Related Modifier Proteins
  • Ubiquitins
  • rho Guanine Nucleotide Dissociation Inhibitor alpha
  • rho Guanine Nucleotide Dissociation Inhibitor beta
  • Paclitaxel

Grants and funding

Lundbeck Foundation (www.lundbeckfonden.com) supported this work through a Junior Group Leader Fellowship to JN. The Novo Nordisk Foundation (www.novonordiskfonden.dk) supported this through institute funding for JN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.